Boston Scientific Co. (NYSE:BSX) Given Consensus Rating of “Moderate Buy” by Analysts

Boston Scientific Co. (NYSE:BSX) has received a consensus rating of “Moderate Buy” from the twenty-one ratings firms that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation, eighteen have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $75.09.

BSX has been the subject of a number of analyst reports. JPMorgan Chase & Co. lifted their target price on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Deutsche Bank Aktiengesellschaft lifted their price objective on Boston Scientific from $63.00 to $73.00 and gave the stock a “hold” rating in a research report on Thursday, April 25th. Citigroup upped their target price on Boston Scientific from $79.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Needham & Company LLC raised their target price on Boston Scientific from $71.00 to $82.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, Mizuho boosted their price target on Boston Scientific from $80.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday, April 25th.

Insider Activity

In other Boston Scientific news, CFO Daniel J. Brennan sold 13,662 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $65.86, for a total transaction of $899,779.32. Following the completion of the sale, the chief financial officer now directly owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Boston Scientific news, CFO Daniel J. Brennan sold 13,662 shares of Boston Scientific stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the transaction, the chief financial officer now directly owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $66.89, for a total transaction of $467,092.87. Following the completion of the sale, the executive vice president now owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The disclosure for this sale can be found here. Insiders sold 78,384 shares of company stock worth $5,395,560 over the last three months. 0.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Boston Scientific

Hedge funds and other institutional investors have recently modified their holdings of the business. Meeder Advisory Services Inc. lifted its holdings in Boston Scientific by 3.3% during the first quarter. Meeder Advisory Services Inc. now owns 23,332 shares of the medical equipment provider’s stock worth $1,598,000 after acquiring an additional 745 shares during the period. Meeder Asset Management Inc. increased its position in shares of Boston Scientific by 7.9% during the 1st quarter. Meeder Asset Management Inc. now owns 4,102 shares of the medical equipment provider’s stock valued at $281,000 after purchasing an additional 299 shares during the last quarter. NorthRock Partners LLC raised its stake in shares of Boston Scientific by 6.8% during the 1st quarter. NorthRock Partners LLC now owns 9,155 shares of the medical equipment provider’s stock worth $627,000 after purchasing an additional 585 shares during the period. Fiduciary Family Office LLC boosted its holdings in shares of Boston Scientific by 42.9% in the 1st quarter. Fiduciary Family Office LLC now owns 14,512 shares of the medical equipment provider’s stock worth $994,000 after buying an additional 4,359 shares during the last quarter. Finally, Concurrent Investment Advisors LLC grew its position in Boston Scientific by 14.7% during the first quarter. Concurrent Investment Advisors LLC now owns 8,301 shares of the medical equipment provider’s stock valued at $569,000 after buying an additional 1,066 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Up 1.2 %

Boston Scientific stock opened at $73.43 on Wednesday. The firm has a market cap of $107.73 billion, a price-to-earnings ratio of 61.71, a PEG ratio of 2.51 and a beta of 0.77. Boston Scientific has a 52-week low of $48.35 and a 52-week high of $74.39. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The firm has a 50 day moving average price of $68.68 and a two-hundred day moving average price of $61.74.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.